stocks logo

LVTX

LAVA Therapeutics NV
$
1.530
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.550
Open
1.5392
VWAP
1.54
Vol
78.85K
Mkt Cap
40.25M
Low
1.520
Amount
121.27K
EV/EBITDA(TTM)
--
Total Shares
26.29M
EV
-26.31M
EV/OCF(TTM)
--
P/S(TTM)
--
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
0.00
-100%
--
--
Estimates Revision
Stock Price
Go Up
up Image
+22.40%
In Past 3 Month
3 Analyst Rating
down Image
-10.46% Downside
Wall Street analysts forecast LVTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LVTX is 1.37 USD with a low forecast of 1.24 USD and a high forecast of 1.50  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
down Image
-10.46% Downside
Current: 1.530
sliders
Low
1.24
Averages
1.37
High
1.50
Jefferies
Buy
to
Hold
downgrade
$3
2025-08-05
Reason
Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
HC Wainwright & Co.
Arthur He
Hold
Reiterates
$1.5
2025-03-31
Reason
HC Wainwright & Co.
Arthur He
Strong Buy
to
Hold
Downgrades
$2 → $1.5
2025-02-27
Reason
HC Wainwright & Co.
Arthur He
Strong Buy
Maintains
$6 → $2
2024-12-20
Reason
Leerink Partners
Daina Graybosch
Buy
to
Hold
Downgrades
$11 → $2
2024-12-12
Reason
Leerink analyst Daina Graybosch downgraded Lava Therapeutics to Market Perform from Outperform with a price target of $2, down from $11, following the company's discontinuation of LAVA-1207, which was in Phase 1 development for metastatic castration-resistant prostate cancer. The firm acknowledges several valid prostate cancer-related challenges that may not necessarily read through to other targets and indications. That said, Leerink finds it difficult to give its platform the benefit of the doubt.
JMP Securities
Reni Benjamin
Buy
to
Hold
Downgrades
$6
2024-12-11
Reason
JMP Securities analyst Reni Benjamin downgraded Lava Therapeutics to Market Perform from Outperform without a price target following the Q3 report. The firm citers a lack of near-term milestones for the downgrade. With LAVA-1207 discontinued, LAVA-1266 Phase 1 underway, and a cash position of $78.9MM, the shares are fairly valued, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for LAVA Therapeutics NV (LVTX.O) is -1.51, compared to its 5-year average forward P/E of -2.02. For a more detailed relative valuation and DCF analysis to assess LAVA Therapeutics NV 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.02
Current PE
-1.51
Overvalued PE
-0.71
Undervalued PE
-3.34

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.32
Undervalued EV/EBITDA
-1.96

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
104.31
Current PS
0.00
Overvalued PS
313.57
Undervalued PS
-104.95

Financials

Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+272.69%
-7.59M
Operating Profit
FY2025Q1
YoY :
+472.20%
-3.48M
Net Income after Tax
FY2025Q1
YoY :
+550.00%
-0.13
EPS - Diluted
FY2025Q1
YoY :
+1244.69%
-11.65M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
+130.72%
-608.14
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

LVTX News & Events

Events Timeline

2025-08-13 (ET)
2025-08-13
16:58:15
Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year
select
2025-08-04 (ET)
2025-08-04
07:40:39
Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR
select
2025-05-14 (ET)
2025-05-14
07:33:05
Lava Therapeutics reports Q1 EPS (13c) vs (2c) last year
select
Sign Up For More Events

News

9.5
08-13Newsfilter
PinnedLAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
7.0
08-08PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
4.0
08-05Benzinga
HC Wainwright & Co. Maintains Neutral on LAVA Therapeutics, Lowers Price Target to $1.24
Sign Up For More News

FAQ

arrow icon

What is LAVA Therapeutics NV (LVTX) stock price today?

The current price of LVTX is 1.53 USD — it has increased 0 % in the last trading day.

arrow icon

What is LAVA Therapeutics NV (LVTX)'s business?

arrow icon

What is the price predicton of LVTX Stock?

arrow icon

What is LAVA Therapeutics NV (LVTX)'s revenue for the last quarter?

arrow icon

What is LAVA Therapeutics NV (LVTX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for LAVA Therapeutics NV (LVTX)'s fundamentals?

arrow icon

How many employees does LAVA Therapeutics NV (LVTX). have?

arrow icon

What is LAVA Therapeutics NV (LVTX) market cap?